Company Overview and News
Condor Petroleum Inc., Calgary, has cemented production casing in a well that logged at least 135 m of net natural gas pay in stacked reservoirs at the edge of Poyraz Ridge gas field under development in northwestern Turkey.
Statoil ASA has submitted a plan for development and operation of the Trestakk discovery on the Halten Bank to the minister for petroleum and energy in Bodo, Norway. Capital expenditures are estimated at 5.5 billion kroner.
The Trinidad and Tobago government has announced it will be having a competitive bid round in the first quarter of 2017 that is likely to have a mix of deepwater and near-shore blocks.
Rawson Resources Ltd., Sydney, has been awarded a permit in the sparsely explored Cape Vogel basin offshore east Papua New Guinea.
Inpex Corp., Tokyo, said an offshore exploratory well encountered a thin natural gas reservoir in a shallow zone and “unexpected, strong gas indications” in the deepest zone, “suggesting the presence of a high-pressure gas column.”
Rawson Resources Limited (Rawson; ASX:RAW), via its majority owned subsidiary Dondonald Limited, has secured a capital investment of approximately A$750,000 from a group of resident PNG Investors. This transaction sees these Investors subscribe for a 33% stake in Dondonald in exchange for cash invested of K1,744,186 ($750,000). Rawson and the group of Investors have also entered into a Put and Call Option, whereby Rawson (at any time over the next 3 years) can Call for purchase of the Investors shares in Dondonald with payment by way of a share placement of up to 15% of the current issued capital of Rawson Resources Limited (capped at 15,832,072 shares).
In its July Oil Market Report, the International Energy Agency states that the “the market is heading to balance remains on track,” but the road ahead is “far from smooth” as revealed by the recent modest fall back in oil prices.
Holders of interests in the Coiron Amargo Block in Argentina’s Nequen basin and a unit of Royal Dutch Shell PLC have entered a series of agreements that would subdivide the southern part of the 100,000-acre tract and adjust holdings and roles (OGJ Online, Nov. 12, 2013).
Rawson Resources Ltd., Sydney, has reported that Udacha natural gas field in South Australia’s Cooper basin retention lease PRL 26 has been brought on stream.
Woodside Energy Ltd. has let a contract to Keppel Offshore & Marine, Singapore, for the modification and upgrade of the Ngujima-Yin floating production, storage, and offloading vessel, which will support the Greater Enfield oil development offshore Western Australia.
Beach Energy Ltd. commenced first production from the Udacha gas field in PRL 26 lincense in the Cooper Basin, South Australia, joint venture partner Rawson Resources Ltd. disclosed Monday.
US oil well completions fell 69% in the second quarter compared with year-ago levels, the American Petroleum Institute estimates in its 2016 Quarterly Well Completion Report.
EnQuest PLC encountered a 67-ft thick oil-bearing column in the Fulmar in its Eagle exploration well in the Greater Kittiwake Area (GKA) in the Central North Sea. The company did not encounter an oil-water contact, which it said represented potential upside volumes on the flank of the structure.
The US Department of the Interior has published a final rule that industry groups fear will enable federal officials to second-guess oil and gas values used in royalty calculations (OGJ Online, Apr. 17, 2015).
Worldwide natural gas demand is expected to rise 1.6%/year during 2014-35, driven by emerging markets, electric power generation, and industry, according to a recent outlook from Cedigaz.
16h - Asif
Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...
16h - Asif
Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...
2018-05-21 - Asif
Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...